STUDY OBJECTIVE: To determine the effect of early and sustained enrollment in a comprehensive cardiac care (CCC) program on all-cause mortality in patients with coronary artery disease (CAD). DESIGN: Retrospective, longitudinal cohort study. DATA SOURCE: Kaiser Permanente Colorado tracking database. PATIENTS: A total of 4896 patients with an incident occlusive CAD event (index event), defined as acute myocardial infarction and/or percutaneous coronary intervention with or without stent placement, between January 1, 1996 and June 30, 2004. MEASUREMENTS AND MAIN RESULTS: All patients were categorized into one of four cohorts by time to enrollment into the CCC program relative to the index event: early CCC-enrolled less than 90 days after the index event (1630 patients), delayed CCC--enrolled 90 days or more after the index event (1211 patients), intermittent CCC--enrolled intermittently with noncontinuous care (483 patients), and no CCC--never enrolled (1572 patients). The primary outcome was all-cause mortality. Patients were censored at death from all causes, end of health plan membership, or study end (December 31, 2005), whichever came first. Patients with any exposure to the CCC were less likely to die compared with the no CCC cohort (p<0.001). After adjusting for baseline covariates, the early, delayed, and intermittent CCC cohorts had reduced hazard rate ratios for all-cause mortality of 0.11 (95% confidence interval [CI] 0.08-0.14), 0.35 (95% CI 0.29-0.44), and 0.54 (95% CI 0.41-0.70), respectively, compared with the no CCC cohort (all p<0.001). CONCLUSIONS: Compared with those not enrolled in the CCC program, patients enrolled in the early CCC were 89% less likely to die. The earlier the program is started after a coronary event, the better the mortality reduction benefit.
STUDY OBJECTIVE: To determine the effect of early and sustained enrollment in a comprehensive cardiac care (CCC) program on all-cause mortality in patients with coronary artery disease (CAD). DESIGN: Retrospective, longitudinal cohort study. DATA SOURCE: Kaiser Permanente Colorado tracking database. PATIENTS: A total of 4896 patients with an incident occlusive CAD event (index event), defined as acute myocardial infarction and/or percutaneous coronary intervention with or without stent placement, between January 1, 1996 and June 30, 2004. MEASUREMENTS AND MAIN RESULTS: All patients were categorized into one of four cohorts by time to enrollment into the CCC program relative to the index event: early CCC-enrolled less than 90 days after the index event (1630 patients), delayed CCC--enrolled 90 days or more after the index event (1211 patients), intermittent CCC--enrolled intermittently with noncontinuous care (483 patients), and no CCC--never enrolled (1572 patients). The primary outcome was all-cause mortality. Patients were censored at death from all causes, end of health plan membership, or study end (December 31, 2005), whichever came first. Patients with any exposure to the CCC were less likely to die compared with the no CCC cohort (p<0.001). After adjusting for baseline covariates, the early, delayed, and intermittent CCC cohorts had reduced hazard rate ratios for all-cause mortality of 0.11 (95% confidence interval [CI] 0.08-0.14), 0.35 (95% CI 0.29-0.44), and 0.54 (95% CI 0.41-0.70), respectively, compared with the no CCC cohort (all p<0.001). CONCLUSIONS: Compared with those not enrolled in the CCC program, patients enrolled in the early CCC were 89% less likely to die. The earlier the program is started after a coronary event, the better the mortality reduction benefit.
Authors: Marsha A Raebel; Jennifer L Ellis; Nikki M Carroll; Elizabeth A Bayliss; Brandy McGinnis; Emily B Schroeder; Susan Shetterly; Stan Xu; John F Steiner Journal: J Gen Intern Med Date: 2011-08-31 Impact factor: 5.128
Authors: Barry L Carter; Christopher S Coffey; Elizabeth A Chrischilles; Gail Ardery; Dixie Ecklund; Brian Gryzlak; Mark W Vander Weg; Paul A James; Alan J Christensen; Christopher P Parker; Tyler Gums; Rachel J Finkelstein; Liz Uribe; Linnea A Polgreen Journal: Pharmacotherapy Date: 2015-06-25 Impact factor: 4.705
Authors: Barry L Carter; Barcey T Levy; Brian Gryzlak; Elizabeth A Chrischilles; Mark W Vander Weg; Alan J Christensen; Paul A James; Carol A Moss; Christopher P Parker; Tyler Gums; Rachel J Finkelstein; Yinghui Xu; Jeffrey D Dawson; Linnea A Polgreen Journal: Contemp Clin Trials Date: 2015-05-04 Impact factor: 2.226
Authors: Michele Wood; Thomas Delate; Sheila L Stadler; Anne M Denham; Leslie K Ruppe; Roseanne Hornak; Kari L Olson Journal: Pharm Pract (Granada) Date: 2019-05-29